Literature DB >> 18501205

Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.

Mandi M Murph1, Giang H Nguyen, Harish Radhakrishna, Gordon B Mills.   

Abstract

Since the molecular cloning of the vzg-1/Edg-2/LPA1 gene, studies have attempted to characterize LPA1 receptor functionality into a single categorical role, different from the other Edg-family LPA receptors. The desire to categorize LPA1 function has highlighted its complexity and demonstrated that the LPA1 receptor does not have one absolute function throughout every system. The central nervous system is highly enriched in the LPA1 receptor, suggesting an integral role in neuronal processes. Metastatic and invasive breast cancer also appears to have LPA-mediated LPA1 receptor functions that enhance phenotypes associated with tumorigenesis. LPA1 possesses a number of motifs conserved among G protein-coupled receptors (GPCRs): a DRY-like motif, a PDZ domain, Ser/Thr predicted sites of phosphorylation, a di-leucine motif, double cysteines in the tail and conserved residues that stabilize structure and determine ligand binding. The third intracellular loop of the LPA1 receptor may be the crux of receptor signaling and attenuation with phosphorylation of Thr-236 potentially a key determinant of basal LPA1 signaling. Mutagenesis data supports the notion that Thr-236 regulates this process since mutating Thr-236 to Ala-236 increased basal and LPA-mediated serum response factor (SRF) signaling activity and Lys-236 further increased this basal signaling. Here we describe progress on defining the major functions of the LPA1 receptor, discuss a context dependent dualistic role as both a negative regulator in cancer and a proto-oncogene, outline its structural components at the molecular amino acid level and present mutagenesis data on the third intracellular loop of the receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18501205      PMCID: PMC2565514          DOI: 10.1016/j.bbalip.2008.04.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  93 in total

1.  Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Authors:  T Furui; R LaPushin; M Mao; H Khan; S R Watt; M A Watt; Y Lu; X Fang; S Tsutsui; Z H Siddik; R C Bast; G B Mills
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

Review 2.  Melanocortin receptors, red hair, and skin cancer.

Authors:  J L Rees; E Healy
Journal:  J Investig Dermatol Symp Proc       Date:  1997-08

3.  Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor.

Authors:  Sarah J Paulsen; Mette M Rosenkilde; Jesper Eugen-Olsen; Thomas N Kledal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.

Authors:  Ahmed Boucharaba; Claire-Marie Serre; Sandra Grès; Jean Sébastien Saulnier-Blache; Jean-Claude Bordet; Julien Guglielmi; Philippe Clézardin; Olivier Peyruchaud
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Arrestin binding to the M(2) muscarinic acetylcholine receptor is precluded by an inhibitory element in the third intracellular loop of the receptor.

Authors:  K B Lee; J A Ptasienski; R Pals-Rylaarsdam; V V Gurevich; M M Hosey
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

Review 6.  Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.

Authors:  X Fang; D Gaudette; T Furui; M Mao; V Estrella; A Eder; T Pustilnik; T Sasagawa; R Lapushin; S Yu; R B Jaffe; J R Wiener; J R Erickson; G B Mills
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

7.  GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion.

Authors:  Sumana Shashidhar; Gustavo Lorente; Usha Nagavarapu; April Nelson; Jane Kuo; Jeramiah Cummins; Karoly Nikolich; Roman Urfer; Erik D Foehr
Journal:  Oncogene       Date:  2005-03-03       Impact factor: 9.867

8.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator.

Authors:  C Bais; B Santomasso; O Coso; L Arvanitakis; E G Raaka; J S Gutkind; A S Asch; E Cesarman; M C Gershengorn; E A Mesri; M C Gerhengorn
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

9.  Phosphorylation and desensitization of the lysophosphatidic acid receptor LPA1.

Authors:  S Eréndira Avendaño-Vázquez; Agustín García-Caballero; J Adolfo García-Sáinz
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

10.  Type I PDZ ligands are sufficient to promote rapid recycling of G Protein-coupled receptors independent of binding to N-ethylmaleimide-sensitive factor.

Authors:  Robert M Gage; Elena A Matveeva; Sidney W Whiteheart; Mark von Zastrow
Journal:  J Biol Chem       Date:  2004-11-17       Impact factor: 5.157

View more
  25 in total

Review 1.  Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer.

Authors:  Shelley B Hooks; Mandi M Murph
Journal:  Future Med Chem       Date:  2015-08-21       Impact factor: 3.808

Review 2.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

3.  Endosomal H2O2 production leads to localized cysteine sulfenic acid formation on proteins during lysophosphatidic acid-mediated cell signaling.

Authors:  Chananat Klomsiri; LeAnn C Rogers; Laura Soito; Anita K McCauley; S Bruce King; Kimberly J Nelson; Leslie B Poole; Larry W Daniel
Journal:  Free Radic Biol Med       Date:  2014-03-21       Impact factor: 7.376

4.  2D binary QSAR modeling of LPA3 receptor antagonism.

Authors:  James I Fells; Ryoko Tsukahara; Jianxiong Liu; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2010-03-07       Impact factor: 2.518

5.  Molecular regulation of lysophosphatidic acid receptor 1 trafficking to the cell surface.

Authors:  Jing Zhao; Jianxin Wei; Rachel K Bowser; Su Dong; Shuqi Xiao; Yutong Zhao
Journal:  Cell Signal       Date:  2014-07-13       Impact factor: 4.315

Review 6.  Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity.

Authors:  Steve N Georas
Journal:  Immunol Res       Date:  2009-01-30       Impact factor: 2.829

7.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.

Authors:  Jean-Claude A Marshall; Joshua W Collins; Joji Nakayama; Christine E Horak; David J Liewehr; Seth M Steinberg; Mary Albaugh; Fernando Vidal-Vanaclocha; Diane Palmieri; Maryse Barbier; Maximilien Murone; Patricia S Steeg
Journal:  J Natl Cancer Inst       Date:  2012-08-21       Impact factor: 13.506

10.  Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Authors:  Mandi M Murph; Wenbin Liu; Shuangxing Yu; Yiling Lu; Hassan Hall; Bryan T Hennessy; John Lahad; Marci Schaner; Aslaug Helland; Gunnar Kristensen; Anne-Lise Børresen-Dale; Gordon B Mills
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.